INSMED ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ARISE STUDY OF ARIKAYCE (AMIKACIN LIPOSOME INHALATION SUSPENSION) IN PATIENTS WITH NTM LUNG DISEASE CAUSED BY MAC

Source :: PR Newswire. September 5, 2023
Publication Year :: 2023
Abstract: -QOL-B Respiratory Domain Shown to Work Effectively as Patient-Reported Outcome Tool in Patients with MAC Lung Disease; to be Proposed to FDA as Primary Endpoint in ENCORE with No Modifications- [...]

Subjects :: United States. Food and Drug Administration
Insmed Inc. -- Product development
Lung diseases -- Care and treatment
Antibacterial agents -- Product development
Pharmaceutical industry -- Product development
Business
News, opinion and commentary
Arikayce (Medication) -- Product development

Tools